The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease-Reference-Cited by-同舟云学术

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease

Published:2023-08-26 Issue:6 Volume:37 Page:873-889
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Müller-Ladner Ulf,Dignass Axel,Gaffney Karl,Jadon Deepak,Matucci-Cerinic Marco,Lobaton Triana,Carron Philippe,Gisbert Javier P.,Pande Ira,Utzinger Maximilian,Addison Janet

Funder

Biogen International GmbH

Justus-Liebig-Universität Gießen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-023-00616-3.pdf

Reference44 articles.

1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–45. https://doi.org/10.1172/JCI36389.

2. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77. https://doi.org/10.1136/ard.2010.140582.

3. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis—shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63–8. https://doi.org/10.1038/nrrheum.2015.171.

4. Watad A, Bridgewood C, Russell T, Marzo-Ortega H, Cuthbert R, McGonagle D. The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol. 2018;9:2668. https://doi.org/10.3389/fimmu.2018.02668.

5. Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50(4):992–1006. https://doi.org/10.1016/j.immuni.2019.03.017.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers;Exploration of Musculoskeletal Diseases;2024-09-10

2. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24